Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C14H18N6O.H2O4S |
| Molecular Weight | 670.743 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.NC1=NC2=C(N=CN2[C@@H]3C[C@H](CO)C=C3)C(NC4CC4)=N1.NC5=NC6=C(N=CN6[C@@H]7C[C@H](CO)C=C7)C(NC8CC8)=N5
InChI
InChIKey=WMHSRBZIJNQHKT-FFKFEZPRSA-N
InChI=1S/2C14H18N6O.H2O4S/c2*15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21;1-5(2,3)4/h2*1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19);(H2,1,2,3,4)/t2*8-,10+;/m11./s1
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
TRIZIVIR (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
TRIUMEQ (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
ZIAGEN (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
KIVEXA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
||
|
NCI_THESAURUS |
C97452
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C28804
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
441384
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
DBSALT000871
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
CHEMBL1380
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
J220T4J9Q2
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
7154
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
221052
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | RxNorm | ||
|
m1271
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | Merck Index | ||
|
JJ-59
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
J220T4J9Q2
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
SUB00231MIG
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
1000408
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
DTXSID40894147
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
2361
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
760063
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
100000090705
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | |||
|
ABACAVIR SULFATE
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY | Description: White to almost white powder. Solubility: Soluble in water. Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). Storage: Abacavir sulfate should be kept in a well-closed container. Definition: Abacavir sulfate contains not less than 99.0% and not more than 101.0% of (C14H18N6O)2,H2SO4 calculated with reference to the anhydrous substance. Manufacture: The production method is validated to demonstrate that the substance, if tested, would comply with a limit of not more than 0.5% for (1R, 4S)-abacavir enantiomer using a suitable chiral chromatographic method. | ||
|
188062-50-2
Created by
admin on Fri Dec 15 15:47:38 UTC 2023 , Edited by admin on Fri Dec 15 15:47:38 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD